Cowen and Company’s ProQR Therapeutics PRQR Stock Holding History

Cowen and Company’s Portfolio PRQR Stock Details PRQR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-377,776	Closed	-$342K	–	727
2022 Q1	$342K	Sell	377,776 -1,187,068	-76%	-$3.98M	0.03%	188
2021 Q4	$12.5M	Buy	1,564,844 +1,298,183	+487%	+$9.89M	1.14%	18
2021 Q3	$2.23M	Hold	266,661	–	–	0.11%	87
2021 Q2	$1.8M	Sell	266,661 -19,035	-7%	-$123K	0.09%	88
2021 Q1	$1.89M	Hold	285,696	–	–	0.13%	82
2020 Q4	$1.2M	Sell	285,696 -12,326	-4%	-$52K	0.11%	70
2020 Q3	$1.43M	Sell	298,022 -2,020	-0.7%	-$10.6K	0.23%	71
2020 Q2	$1.82M	Sell	300,042 -54,807	-15%	-$296K	0.3%	57
2020 Q1	$1.95M	Buy	354,849 +251,122	+242%	+$1.93M	0.45%	50
2019 Q4	$1.03M	Buy	+103,727	New	+$808K	0.09%	89

Other funds holding PRQR

PFM

Privium Fund Management Amsterdam, Netherlands $480M AUM 77.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

MCM

M28 Capital Management Stamford, Connecticut $53.8M AUM 28.63% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

MAM

Monaco Asset Management Monaco $542M AUM 54.4% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Cowen and Company's PRQR Position: Q2 2022 in Review

Cowen and Company sold out of ProQR Therapeutics (PRQR) in Q2 2022, closing a stake of 377,776 shares — an estimated $342K sold.

Cowen and Company first reported a position in PRQR in Q4 2019 and held it in 10 quarters. The position peaked at $12.5M in Q4 2021. 51 funds tracked by Wall St. Rank hold PRQR as of Q2 2022.

Cowen and Company reported no remaining ProQR Therapeutics position as of Q2 2022 after selling out during the quarter.
Cowen and Company sold 377,776 ProQR Therapeutics shares in Q2 2022, an estimated $342K.
Cowen and Company first reported a position in ProQR Therapeutics in Q4 2019 and held it in 10 quarters.
Cowen and Company's ProQR Therapeutics position peaked at $12.5M in Q4 2021.
51 funds tracked by Wall St. Rank held ProQR Therapeutics as of Q2 2022.

Based on Cowen and Company's 13F filing for Q2 2022, filed 5 Aug 2022.